Sanofi

Open: 48.71 Close: 49.08 Change: 0.37

The stock market through the eyes of an AI: Sanofi Stock.

The game is changing. There is a new strategy to evaluate Sanofi fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, end, trial, lung, cancer, develop, drug, and the …

Concept Map

Semantic Network

Stock Summary

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company also provides cough, cold.

Today's Summary

Kymera Therapeutics continues to cash in on its up-to-$2 billion collaboration with Sanofi. Exscientia plc announced a new discovery stage programme with Sano. Jefferies Sticks to its Buy Rating for Sanofi (SNYNF)

Today's News

Sanofi drops sole clinical-stage adc over ph. 3 lung cancer fail. Sanofi to end tusamitamab ravtansine development after trial failure. Kymera Therapeutics continues to cash in on its up-to-$2 billion collaboration with Sanofi. Targeted protein degradation therapy developer generates $55M in milestone payments from partnership to develop lead candidate in atopic dermatitis, hidradenitis suppurativa. Sanofi ends lung cancer drug study after trial failure - bloomberg. sanofi ends. sanofi ending lung cancer. medicine after it failed to impress in a late-stage trial. Ligand Pharmaceuticals Incorporated announced that it has acquired Tolerance Therapeutics, Inc. and Sanofi launched The 1 Pledge movement to drive early screening for type 1 diabetes in the U.S. Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence. Evidation and Sanofi have pioneered to translate person-generated health data into quantified clinical and economic outcomes, a key priority for both companies. Sanofi and Aetion are taking a digital approach to clinical trials, partnering with Science 37, a clinical research services and technology company based in California. Sanofi Pasteur and Immune Design will each contribute product candidates. Sanofi and Immune Design have entered into a licensing agreement for use of Immune Designs GLAASTM discovery platform to develop therapeutic agents to treat a selected food allergy. Immune design has granted Sanofi an exclusive license to discover, develop and commercialize products to treat food allergies. Sanofi Sees Annual Sales From New Pharma Assets Above $10.8 Bln by 2030. Sanofi ends drug program after late-stage trial in Lung Cancer Fails. Exscientia plc (Nasdaq: EXAI) announced a new discovery stage programme with Sanofi to design a potential best-in-class molecule. Jefferies Sticks to Its Buy Rating for Sanofi (SNYNF) Sanofi (SNY) Stock said it was discontinuing development of tusamitamab ravtansine after a Phase 3 study of the drug failed to meet its dual primary endpoints. Sanofi was testing the drug in patients with non-small cell lung cancer whose tumors expressed high levels of the biomarker. Sanofi dropped a planned licensing agreement with Maze Therapeutics to develop treatments for Pompe disease. The FTC argued that Sanofi gaining control of Mazes lead asset MZE001 would give the former a monopoly in the space and lead to higher costs for patients.

Stock Profile

"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France."

Keywords

This document will help you to evaluate Sanofi without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, end, trial, lung, cancer, develop, drug, and the most common words in the summary are: sanofi, bloomberg, product, company, market, news, drug, . One of the sentences in the summary was: Exscientia plc announced a new discovery stage programme with Sano. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #sanofi #bloomberg #product #company #market #news #drug.